US 11,771,681 B2
Therapeutic compounds
Peter Rands, London (GB); Zelah Joel, London (GB); and Tiffanie Benway, London (GB)
Assigned to SMALL PHARMA LTD, London (GB)
Filed by SMALL PHARMA LTD, London (GB)
Filed on Jun. 2, 2020, as Appl. No. 16/890,664.
Claims priority of application No. 1907871 (GB), filed on Jun. 3, 2019.
Prior Publication US 2020/0390746 A1, Dec. 17, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4045 (2006.01)
CPC A61K 31/4045 (2013.01) [C07B 2200/05 (2013.01)] 9 Claims
 
1. A deuterium-enriched N,N-dimethyltryptamine mixture consisting essentially of:
N,N-dimethyltryptamine, including pharmaceutically acceptable salts thereof; and
50% or more by weight in total of α-protio, α-deutero-N,N-dimethyltryptamine of the formula

OG Complex Work Unit Chemistry
including pharmaceutically acceptable salts thereof; and
α,α-dideutero-N,N-dimethyltryptamine of the formula

OG Complex Work Unit Chemistry
including pharmaceutically acceptable salts thereof;
wherein the mixture comprises 2% or more by weight of the α-protio, α-deutero-N,N-dimethyltryptamine, including pharmaceutically acceptable salts thereof; and
wherein the deuterium-enriched N,N-dimethyltryptamine mixture has a purity of greater than or equal to 99% by HPLC.